CPHI Milan 2
CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical
Volume 15 Issue 3

Antibody Drug Conjugates and the Link to Fighting Cancer

Antibody drug conjugates (ADCs) are a big deal in oncology. And rightly so: they combine highly specific targeting with a potent cytotoxic payload to deliver tremend...
Continue Reading →
Volume 14 Issue 4

EU CTR: Final Countdown, What You Need to Know

The end of the transition period is imminent. How can clinical trial sponsors and CROs ease the transition to CTIS? Soon, the one-year transition period of the EU...
Continue Reading →
Volume 14 Issue 4

Brexit – Impact, Challenges, and Solutions for The Pharmaceutical Industry

Brexit has provided several challenges to the pharmaceutical industry that required robust actions and swift resolution in order to remain in compliance following th...
Continue Reading →
News

CHMP recommends approval of Cablivi(TM) (caplacizumab)

First therapeutic to receive positive CHMP opinion for treatment of a rare blood disorder called acquired thrombotic thrombocytopenic purpura The European Me...
Continue Reading →
News

WuXi STA first CDMO to support the approval of an innovative drug in China through the “MAH” pilot

WuXi STA enables Ascletis to receive NDA Approval from China FDA for Ganovo® STA Pharmaceutical Co., Ltd. (WuXi STA), a subsidiary of WuXi AppTec, announces that its...
Continue Reading →
News

GSK Applies in Japan for Approval of a Once-Daily, Single Inhaler Triple Therapy for COPD

First filing made for a triple therapy for chronic obstructive pulmonary disease offered in a single inhaler. Chronic obstructive pulmonary disease (COPD) affects...
Continue Reading →
News

Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Newly Diagnosed Multiple Myeloma

DARZALEX (daratumumab) approved by U.S. FDA in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple mye...
Continue Reading →
News

Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 Mutations

Invivoscribe Technologies, Inc. announced today that they have submitted to Japan's Pharmaceutical and Medical Devices Agency (PMDA) and the US Food and Drug Adminis...
Continue Reading →
News

FDA approval for Novartis' melanoma combo

The FDA has approved Novartis' Tafinlar(dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment of BRAF V600E or V600K mutation-positiv...
Continue Reading →
News

Wickham Laboratories Holdings Announces Planning Application Approval

Outline planning permission application for expansion of the Hoeford Point site now approved. Wickham Laboratories Holdings, owner of Wickham Laboratories Ltd...
Continue Reading →

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026